IFNG and Sjogren syndrome: DMSCs improve the immunoregulatory effects on T and B lymphocyte responses based on decreasing CD4+ T lymphocyte proliferation, intracellular Interferon-gamma (IFN-γ), and IL-17 secretion in primary Sjögren’s syndrome [43].